Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameEuroeyes
Stock Code01846
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities在德國、丹麥及中國提供視力矯正服務,包括屈光性激光手術、後房型人工晶體(ICL)植入術、晶體置換手術及其他。
Listing Date2019-10-15
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)香港銅鑼灣羅素街2-4號2000年廣場 3樓
Business Address (Hong Kong)香港銅鑼灣勿地臣街1號時代廣場二座3711室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websiteeuroeyes.hk
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 7.50 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueRMB 0.01 / shares
Offer Period2019-09-30 to 2019-10-08
Global Offering Shares79,334,000 shares
HK Public Offer Shares (Initial)7,934,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)71,400,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO317,334,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 595,005,000

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 1,000 HK$ 7,500
2 lots 2,000 HK$ 15,000
3 lots 3,000 HK$ 22,500
4 lots 4,000 HK$ 30,000
5 lots 5,000 HK$ 37,500
6 lots 6,000 HK$ 45,000
7 lots 7,000 HK$ 52,500
8 lots 8,000 HK$ 60,000
9 lots 9,000 HK$ 67,500
10 lots 10,000 HK$ 75,000
15 lots 15,000 HK$ 112,500
20 lots 20,000 HK$ 150,000
25 lots 25,000 HK$ 187,500
30 lots 30,000 HK$ 225,000
35 lots 35,000 HK$ 262,500
40 lots 40,000 HK$ 300,000
45 lots 45,000 HK$ 337,500
50 lots 50,000 HK$ 375,000
60 lots 60,000 HK$ 450,000
70 lots 70,000 HK$ 525,000
80 lots 80,000 HK$ 600,000
90 lots 90,000 HK$ 675,000
100 lots 100,000 HK$ 750,000
150 lots 150,000 HK$ 1,125,000
200 lots 200,000 HK$ 1,500,000
250 lots 250,000 HK$ 1,875,000
300 lots 300,000 HK$ 2,250,000
350 lots 350,000 HK$ 2,625,000
400 lots 400,000 HK$ 3,000,000
450 lots 450,000 HK$ 3,375,000
500 lots 500,000 HK$ 3,750,000
600 lots 600,000 HK$ 4,500,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
700 lots 700,000 HK$ 5,250,000
800 lots 800,000 HK$ 6,000,000
900 lots 900,000 HK$ 6,750,000
1,000 lots 1,000,000 HK$ 7,500,000
1,500 lots 1,500,000 HK$ 11,250,000
2,000 lots 2,000,000 HK$ 15,000,000
2,500 lots 2,500,000 HK$ 18,750,000
3,000 lots 3,000,000 HK$ 22,500,000
3,500 lots 3,500,000 HK$ 26,250,000
3,967 lots 3,967,000 HK$ 29,752,500

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 791.8M
Est. Threshold HK$ 9.44B
Analysis Result HK market cap below threshold, need +1093%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約4.3百萬歐元
Period-End Cash Balance歐元16.6百萬元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201620172018
Revenue 30,40236,97742,961
Cost of sales -20,485-23,848-25,545
Gross profit 9,91713,12917,416
Other income and gains, net 1948,283238
Selling and distribution expenses -4,567-5,676-5,529
Administrative expenses -1,569-1,745-3,883
Operating profit 3,96513,9968,156
Net finance costs -787-1,267-825
Profit before tax 3,17812,7297,331
Income tax expense -1,239-4,158-3,040
Profit for the year 1,9398,5714,291
Profit attributable to owners 2,3768,7073,833
Balance Sheet
Item 2016201720182019-03
Cash and cash equivalents 5,3966,55616,558
Trade and bills receivables 411327517
Inventories 1,2361,6923,458
Total current assets 8,46218,57123,909
Total assets 39,83948,27765,943
Total current liabilities 13,41215,76916,862
Total liabilities 28,00027,35639,268
Total equity 11,83920,92126,675
Equity attributable to owners 10,92119,99325,288
Interest-bearing borrowings 2,1362,33548533
Cash Flow Statement
Item 2016201720182019-03
Net cash from operating activities -3428,85017,495
Net cash from investing activities -2,362-3,959-2,130
Net cash from financing activities -1,426-3,645-5,380
Net increase in cash -4,1301,2469,985
Purchase of PP&E -1,505-4,057-2,220-874
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 11.0
First Day OpenHK$ 14.2
First Day Change46.67%
First Day Volume99111000.0
First Day Turnover1248930000.0
Use of Proceeds
1、約210.7百萬港元(占估計所得款項凈額總數的約40.0%)用于在中國主要城市(包括成都和重慶)設立診所; 2、約173.8百萬港元(占估計所得款項凈額總數的約33.0%)用于可能收購歐洲的診所集團; 3、約89.5百萬港元(占估計所得款項凈額總數的約17.0%)用于加大我們的營銷力度; 4、約52.7百萬港元(占估計所得款項凈額總數的約10.0%)用于我們的營運資金及用于一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
中银国际亚洲有限公司 CE AET863
Overall Coordinators (1)
中银国际亚洲有限公司 CE AET863
Joint Bookrunners (3)
中银国际亚洲有限公司 CE AET863 中信建投(国际)融资有限公司 CE BAU112 Fosun International Securities Limited CE AAF432
Joint Lead Managers (3)
中银国际亚洲有限公司 CE AET863 中信建投(国际)融资有限公司 CE BAU112 Fosun International Securities Limited CE AAF432

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
ChairmanJørn Slot Jørgensen—
Company Secretary梁庭彰—
No director data available.

Major Shareholders

Major Shareholders & HoldingsJørgensen醫生持股52.84%,Susanne Jørgensen醫生(配偶權益)持股52.84%;靈銳國際持股7.28%,由CHINAEYES Limited、TOPGOOD Inc.、AIRUIKANG Holdings Limited及徐旭陽先生最終持有。
About this page

This page shows Euroeyes (01846) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect